Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.70 |
| ▸ | INSR | P06213 | 7/20 | 0.70 |
| ▸ | IGF1R | P08069 | 7/20 | 0.70 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.67 |
| ▸ | AURKA | O14965 | 2/20 | 0.67 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | STK10 | O94804 | 2/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | FES | P07332 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | YES1 | P07947 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104330 | 0.92 | ZAP70 (0.79) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL4099900 | 0.90 | EGFR (0.70) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL26451583 | 0.90 | EGFR (0.77) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL30123962 | 0.90 | EGFR (0.77) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL381697 | 0.88 | ZAP70 (0.76) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL18843559 | 0.86 | ALK (0.87) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL4095997 | 0.85 | ALK (0.75) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL4100628 | 0.84 | ALK (0.81) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL4094622 | 0.84 | ALK (0.62) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL13394910 | 0.84 | ALK (0.84) | EGFRALKINSRIGF1RZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | EGFR 3112/4885ALK 2060/4885INSR 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.